ストックスクリーナーアプリを入手
0.0688
21.01%
-0.0183
アフターアワーズ：
.07
0.0012
+1.74%
前日終値:
$0.0871
開ける：
$0.0698
24時間の取引高:
5,664
Relative Volume:
8.34
時価総額：
$N/A
収益：
-
当期純損益:
$-16.08M
株価収益率:
-0.002
EPS:
-34.43
ネットキャッシュフロー:
$-11.54M
1週間 パフォーマンス:
-21.01%
1か月 パフォーマンス:
-21.01%
6か月 パフォーマンス:
-86.27%
1年 パフォーマンス:
-97.18%
1日の値動き範囲:
$0.0618
$0.0698
1週間の範囲:
$0.0618
$0.0698
52週間の値動き範囲:
$0.0618
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.0688 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-11 | 開始されました | ROTH Capital | Buy |
| 2017-11-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-04-18 | 開始されました | Rodman & Renshaw | Buy |
| 2014-06-02 | 再開されました | Maxim Group | Buy |
| 2014-05-09 | 開始されました | Maxim Group | Buy |
すべてを表示
Bio Path Holdings Inc (BPTH) 最新ニュース
[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
North American Morning Briefing : Dow Futures Stall Ahead of Key Data -2- - marketscreener.com
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - Sahm
Top News Today: Stocks Mixed as Energy Rises, Tech Falls - 富途牛牛
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
North American Morning Briefing : Stock Futures Rise as 2026 Trading Year Begins - MarketScreener
Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld MedTech
What analyst consensus implies for Bio Path Holdings Inc. (IBP0) stockJuly 2025 Rallies & Daily Profit Focused Stock Screening - Улправда
Why analysts recommend Bio Path Holdings Inc. (IBP0) stock2025 Short Interest & Weekly Breakout Watchlists - Улправда
North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2- - marketscreener.com
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Armistice Capital LLC Trims Holdings in UiPath, Inc. $PATH - Defense World
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Critical Survey: NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Bio-Path (NASDAQ:BPTH) - Defense World
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
P 500 performance this yearInflation Watch & Technical Pattern Alert System - Newser
Can Bio Path Holdings Inc. (IBP0) stock retain market dominanceJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears - GlobeNewswire
What consensus target says about Bio Path Holdings Inc. (IBP0) stockJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Analyzing Aadi Bioscience (NASDAQ:AADI) & Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path reports positive trial outcomes for cancer treatments - MSN
RNA Interference Pipeline Insights Report 2025: DelveInsight Highlights Emerging Therapeutics Transforming the Future Treatment Landscape - Barchart.com
Axos Financial loses $15M indemnification fight after merger trading fiasco - InvestmentNews
Bio-Path Holdings Inc. (BPTH) Stock Price | Live Quotes & Charts | PINL - StocksToTrade
MSN Money - MSN
North American Morning Briefing : Stock Futures Mostly Lower, AI Volatility Persists -2- - MarketScreener
Bio-Path Holdings Delays 10-Q Filing - MSN
Why ETFs are accumulating Bio Path Holdings Inc. (IBP0) stockTrade Volume Summary & Safe Entry Zone Tips - newser.com
Will Bio Path Holdings Inc. (IBP0) stock benefit from infrastructure billJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Bio Path Holdings Inc. (IBP0) stock a fit for income portfoliosTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Bio Path Holdings Inc (BPTH) 財務データ
収益
当期純利益
現金流量
EPS
2.90%
2.73%
大文字化:
|
ボリューム (24 時間):